Coronary disease & ACSCohort study
Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention
- Cohort study
- single-centre
Authors' conclusion
Among statin-treated patients undergoing PCI, residual inflammation but not cholesterol risk was associated with an increased risk of MACE during follow-up.
Study context
- Population
- Statin-treated patients undergoing percutaneous coronary intervention (PCI) at a tertiary centre, 2012–2022 (excluding acute MI, cancer, hs-CRP >10 mg/L)
- Participants
- 15,494 patients
- Exposure
- Residual cholesterol and/or inflammatory risk vs no residual risk
- Outcome
- MACE:
- All-cause mortality
- Spontaneous MI
- Stroke
- Follow-up
- 1 year after index PCI
Main finding
As reported in the abstract
MACE · 1 year
Residual inflammatory risk
5.1%
Each group vs no residual riskAdjusted hazard ratio (95% CI)P value
Residual inflammatory risk
1.78(1.36–2.33)
P < 0.001Combined residual risk
1.56(1.19–2.04)
P = 0.001- Residual cholesterol risk
- adjusted HR 1.01 (95% CI .76-1.35); P = 0.920
Observational data: associations, not effects.
Original publication
Residual cholesterol and inflammatory risk in statin-treated patients undergoing percutaneous coronary intervention. Eur Heart J. Published 10 April 2025. doi:10.1093/eurheartj/ehaf196
Summarised from the published abstract; every number is checked against it